Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Teva Pharma Japan Renamed “Teva Takeda Pharma”
October 3, 2016
- Takecab Most Heavily Promoted Drug in August: Anterio
October 3, 2016
- Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
September 30, 2016
- Daiichi Sankyo, Zymeworks Seal Immuno-Oncology Cross-Licensing Pact
September 30, 2016
- Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
September 29, 2016
- Maruho Gets Rights to Astellas’ JAK Inhibitor for Skin Diseases
September 29, 2016
- Pruritus Drug Remitch Filed for Use in Peritoneal Dialysis Patients
September 29, 2016
- Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
September 28, 2016
- Celgene Poised to Boost Japan Organization as New Launch Nears
September 28, 2016
- Psoriasis Drug Lumicef to Hit Shelves on Sept. 30: Kyowa Kirin
September 28, 2016
- Sawai Files Myrbetriq Generic in US, Its 2nd Product after Livalo Copy
September 28, 2016
- Eisai Seeks Label Expansion for Fycompa to Include Monotherapy
September 28, 2016
- Novel MR Antagonist Enters Japan PIII for Hypertension: Daiichi Sankyo
September 28, 2016
- Otsuka-Lundbeck’s Alzheimer’s Med Idalopirdine Stumbles in PIII
September 27, 2016
- Rexulti OK’ed for Schizophrenia Maintenance Therapy in US
September 27, 2016
- Daiichi Sankyo Seeks RA Indication for Pralia
September 26, 2016
- Takeda, France’s Affilogic Join Hands on CNS Drugs
September 23, 2016
- Takeda Ties Up with India’s Zydus Cadila for Chikungunya Vaccine
September 23, 2016
- Maruho Gets Japan Rights to Dermira’s Hyperhidrosis Treatment
September 23, 2016
- Sumitomo Dainippon’s ADHD Drug Meets Primary Endpoint in US PII/III Study in Children
September 23, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…